EUVIMEDEUVIMED entdecken
Crossref

Real-world outcomes for primary and secondary central nervous system lymphoma

Başak Bostankolu Değirmenci, Zübeyde Nur Özkurt, Zeynep Arzu Yeğin, Abdullah Münci Yağcı

Journal of Current Hematology & Oncology Research · 13.11.2026 · 4 (4) · 120-124

DOI: 10.51271/jchor-0094 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Current Hematology & Oncology Research, online erschienen am 13.11.2026. Verfasst von Başak Bostankolu Değirmenci und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Central nervous system lymphoma (CNSL) is a rare and aggressive subtype of extranodal non-Hodgkin lymphoma, including primary and secondary forms. Despite advances in treatment, outcomes remain suboptimal. In this study, real-world treatment outcomes and prognostic factors in CNSL patients were evaluated.

Methods

The study should be described, including selection criteria, design (randomized, retrospective/prospective, etc.), and statistical methods applied, if applicable.

Results

The median age was 53 years, and 62.5% of patients had primary CNSL. High-dose methotrexate-based regimens yielded high response rates, with overall response rates of 92.3% for the MATRix regimen and 86.7% for the modified Bonn protocol. Autologous stem cell transplantation (ASCT) was associated with an improvement in complete/unconfirmed complete response rates (52.5% pre-ASCT vs. 65% post-ASCT). At a median follow-up of 1124 days, the overall survival and progression-free survival rates were 52.5% and 35%, respectively. Relapse occurred in 50% of patients. Prognostic scoring systems demonstrated limited applicability due to missing data and the small sample size.

Conclusion

High-dose methotrexate-based regimens followed by ASCT remain effective in CNSL; however, relapse rates remain high. Improved prognostic models and novel therapies are needed.

Zitieren

APA

Değirmenci, B. B., Özkurt, Z. N., Yeğin, Z. A., & Yağcı, A. M. (2026). Real-world outcomes for primary and secondary central nervous system lymphoma. Journal of Current Hematology & Oncology Research, 4(4), 120-124. https://doi.org/10.51271/jchor-0094

Vancouver

Değirmenci BB, Özkurt ZN, Yeğin ZA, Yağcı AM. Real-world outcomes for primary and secondary central nervous system lymphoma. Journal of Current Hematology & Oncology Research. 2026;4(4):120-124. doi:10.51271/jchor-0094

BibTeX
@article{Deirmenci2026,
  author = {Değirmenci, Başak Bostankolu and Özkurt, Zübeyde Nur and Yeğin, Zeynep Arzu and Yağcı, Abdullah Münci},
  title = {Real-world outcomes for primary and secondary central nervous system lymphoma},
  journal = {Journal of Current Hematology & Oncology Research},
  year = {2026},
  volume = {4},
  number = {4},
  pages = {120--124},
  doi = {10.51271/jchor-0094}
}
Kostenlos starten →